SRA 737

Drug Profile

SRA 737

Alternative Names: CCT-245737; PNT-737; SRA737

Latest Information Update: 02 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cancer Research Technology; Sareum; The Institute of Cancer Research
  • Developer Sierra Oncology
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Checkpoint kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer; Solid tumours

Most Recent Events

  • 08 Nov 2017 Sierra Oncology plans combination trials of SRA 737 with PARP inhibitors and other immuno-oncology agents for Cancer
  • 27 Oct 2017 Pharmacodynamics data from a preclinical study in Cancer presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017
  • 05 Jun 2017 Preliminary pharmacokinetics data from a phase I trial in Cancer released by Sierra Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top